Table 4 Likelihood of clinical outcomes by liver dysfunction in patients with vancomycin (adjusted odds ratios and their 95% confidence intervals)

Liver dysfunction

No to mild

1

1

1

1

Moderate to severe

2.48

(0.98- 6.28)

2.79

(1.26-6.18)

2.31

(1.36 -3.93)

1.79

(1.09-2.96)

Daily dose of vancomycin

  < 3000 mg

1

1

1

1

  ≥ 3000 mg

1.85

(0.68-5.07)

0.46

(0.19-1.09)

2.76

(1.51-5.04)

1.59

(0.91-2.77)

Gender

 Female

1

1

1

1

 Male

4.99

(1.13-22.05)

1.36

(0.59-3.14)

0.69

(0.40-1.19)

0.58

(0.35-0.96)

Age (years)

 18–64

1

1

1

1

  ≥ 65

1.99

(0.74-5.40)

1.48

(0.66-3.33)

1.43

(0.78-2.63)

0.91

(0.50-1.65)

Body mass index (kg/m²)

  < 25

1

1

1

1

 25–29.9

0.62

(0.19-2.04)

1.22

(0.48-3.06)

0.46

(0.22-0.93)

0.65

(0.35-1.18)

  ≥ 30

0.95

(0.34-2.61)

0.76

(0.32-1.83)

0.72

(0.40-1.29)

0.37

(0.21-0.68)

Charlson comorbidity index

 0-1

1

1

1

1

  ≥ 2

0.73

(0.29 -1.83)

2.72

(1.15-6.42)

1.68

(0.98-2.87)

1.26

(0.76-2.09)